We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+13.51%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$317M
AUM Growth
-$24.6M
Cap. Flow
-$24.5M
Cap. Flow %
-7.74%
Top 10 Hldgs %
86.56%
Holding
22
New
1
Increased
4
Reduced
8
Closed
1

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$6.43M
2
MIST icon
Milestone Pharmaceuticals
MIST
+$3.06M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$1.72M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$1.11M
5
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$1.02M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$18.8M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$9.87M
3
KALV
KalVista Pharmaceuticals
KALV
+$4.61M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.25M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$1.27M

Sector Composition

Rank Sector Weight
1 Healthcare 98.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$17B
$58.1M 18.3%
504,210
– –
SWAV
2
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$51.5M 16.22%
901,256
– –
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$42.2M 13.29%
962,903
-175,172
-15% -$9.87M
OBSV
4
DELISTED
ObsEva SA Ordinary Shares
OBSV
$25.5M 8.03%
2,252,460
– –
AXSM icon
5
Axsome Therapeutics
AXSM
$12.2B
$23M 7.25%
892,946
+320,990
+56% +$6.43M
RARX
6
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$20.4M 6.42%
677,164
+44,684
+7% +$1.02M
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$17.3M 5.45%
362,010
– –
TCDA
8
DELISTED
Tricida, Inc. Common Stock
TCDA
$16.9M 5.33%
428,731
-533,964
-55% -$18.8M
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.31B
$10.9M 3.43%
2,874,602
-374,562
-12% -$2.25M
CNST
10
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$8.92M 2.81%
726,677
– –
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$8.35M 2.63%
376,889
-196,593
-34% -$4.61M
KNSA icon
12
Kiniksa Pharmaceuticals
KNSA
$4.7B
$8.25M 2.6%
609,081
-30,149
-5% -$468K
SPRO icon
13
Spero Therapeutics
SPRO
$90.9M
$5.46M 1.72%
474,015
– –
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.49B
$5.17M 1.63%
426,781
+155,404
+57% +$1.72M
LJPC
15
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.79M 1.51%
518,102
+146,702
+39% +$1.11M
MIST icon
16
Milestone Pharmaceuticals
MIST
$154M
$4.03M 1.27%
+148,560
New +$3.06M
MRNS
17
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.09M 0.97%
185,969
– –
BLPH
18
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$2.49M 0.79%
276,625
– –
KDMN
19
DELISTED
Kadmon Holdings, Inc.
KDMN
$514K 0.16%
249,463
-570,660
-70% -$1.27M
MTVA
20
MetaVia Inc
MTVA
$9.3M
$382K 0.12%
7
-1
-13% -$73.2K
KA
21
DELISTED
Kineta, Inc. Common Stock
KA
$128K 0.04%
934
-2,117
-69% -$329K
ORTX
22
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-1,238
Closed -$221K

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q2 2019 Portfolio in Review

As of Q2 2019, VHCP Management II held 22 positions worth $317M, down 7.2% from $342M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

VHCP Management II withdrew a net $24.5M in Q2 2019, closing 1 position and reducing 8 holdings. Its most notable exit was Orchard Therapeutics plc American Depositary Shares, an estimated $221K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

Against the trend, VHCP Management II opened a new position in Milestone Pharmaceuticals worth $4.03M.

  • VHCP Management II's largest Q2 2019 buy was Milestone Pharmaceuticals: 148,560 shares worth $4.03M.
  • VHCP Management II added most to Axsome Therapeutics in Q2 2019, an estimated $6.43M increase.
  • VHCP Management II's biggest Q2 2019 reduction was Tricida, Inc. Common Stock, cutting an estimated $18.8M.
  • VHCP Management II fully exited Orchard Therapeutics plc American Depositary Shares in Q2 2019, selling an estimated $221K.
  • VHCP Management II's ten largest holdings make up 87% of its $317M portfolio in Q2 2019.
  • VHCP Management II opened 1 new position and closed 1 in Q2 2019.
  • VHCP Management II's portfolio value fell 7.2% quarter-over-quarter to $317M.

Based on VHCP Management II's 13F filing for Q2 2019, filed 13 Aug 2019.